Transitioning from Adderall to Strattera (Atomoxetine)

You can safely initiate atomoxetine while continuing Adderall, then taper the stimulant over 1–2 weeks once atomoxetine reaches therapeutic dosing—this cross-taper approach maintains ADHD symptom control during the transition period and is supported by clinical trial data. 1

Why a Cross-Taper Is Recommended

Atomoxetine requires 6–12 weeks to achieve full therapeutic effect (median time to response is 3.7 weeks), whereas stimulants work within days. 2, 3 Abruptly stopping Adderall would leave the patient without adequate ADHD coverage during this lag period.
A stepwise cross-titration allows better control of ADHD symptoms during the intervening period by maintaining stimulant coverage while atomoxetine builds to therapeutic levels. 1
Atomoxetine can be co-administered with methylphenidate (and by extension, amphetamines like Adderall) during the switching period without undue concern for adverse events, although blood pressure and heart rate monitoring is necessary. 4, 1

Step-by-Step Transition Protocol

Week 1: Initiate Atomoxetine at Low Dose + Continue Full-Dose Adderall

Start atomoxetine at 0.5 mg/kg/day (approximately 40 mg for most adults) once daily in the morning, while continuing the patient's current full dose of Adderall. 1
This low starting dose minimizes early adverse events (nausea, somnolence, fatigue) that are most common in the first several weeks. 4, 2

Week 2: Increase Atomoxetine + Reduce Adderall by Half

Increase atomoxetine to 1.2 mg/kg/day (approximately 80 mg for most adults), and simultaneously reduce Adderall to half the original dose. 1
The target atomoxetine dose for adults is 60–100 mg daily (maximum 1.4 mg/kg/day or 100 mg, whichever is lower). 5, 6, 2

Week 3 Onward: Atomoxetine Monotherapy

Discontinue Adderall completely and continue atomoxetine at 1.2 mg/kg/day (or the maximum tolerated dose up to 100 mg). 1
Atomoxetine may be discontinued abruptly without rebound effects or discontinuation syndrome, but Adderall should be tapered as described to avoid potential rebound hyperactivity or mood lability. 4

Weeks 3–8: Titration and Evaluation Period

A trial period of at least 6–8 weeks is recommended before evaluating the overall tolerability and efficacy of atomoxetine. 4, 3 Some patients may require up to 12 weeks or longer to reach full response. 2, 3
If the patient is not responding adequately by week 6–8, consider increasing the dose (if below 100 mg) or switching to an alternative non-stimulant (e.g., extended-release guanfacine). 7, 8

Alternative Approach: Direct Switch Without Overlap

If the patient cannot tolerate any overlap period (e.g., due to severe stimulant side effects), atomoxetine can be started immediately after stopping Adderall, but expect a 3–8 week gap in optimal symptom control. 2, 3
Atomoxetine may be initiated by a schedule of dose increases without cross-tapering, though this approach is less preferred because it leaves the patient vulnerable to symptom worsening during the lag period. 4

Monitoring During the Transition

Cardiovascular Monitoring

Measure blood pressure and heart rate at baseline, weekly during the cross-taper, and at each follow-up visit. 4, 1, 2 Atomoxetine causes statistically (but not clinically) significant increases in heart rate (mean +9.2 bpm) and blood pressure (mean +2.4 mm Hg systolic and diastolic). 1, 2
Atomoxetine should be used with caution in patients with hypertension or significant cardiovascular disorders. 6

Symptom Tracking

Use standardized ADHD rating scales (e.g., ADHD-RS-IV) at baseline, week 2, week 4, and week 6–8 to objectively assess symptom improvement. 1
Approximately 50% of non-responders to methylphenidate will respond to atomoxetine, and approximately 75% of responders to methylphenidate will also respond to atomoxetine. 4 Similar response patterns are expected for amphetamine-based stimulants like Adderall.

Adverse Event Monitoring

Common adverse events in the first several weeks include somnolence, fatigue, decreased appetite, nausea, headache, and abdominal pain. 4, 1, 2 These are typically mild to moderate and often resolve with continued treatment.
A slow titration schedule with divided doses (e.g., morning and evening) minimizes the impact of adverse events, though once-daily dosing is also effective. 4, 2
Screen for suicidal ideation at baseline and regularly during treatment, as atomoxetine carries an FDA black-box warning for increased suicidal ideation in children and adolescents (though the absolute risk is low). 2, 3

Growth and Weight Monitoring

Track weight at each visit, as atomoxetine commonly causes decreased appetite and weight loss, though this typically returns to normal in the longer term. 2

Clinical Scenarios Where This Transition Is Appropriate

Incomplete response to Adderall (failure to obtain full reduction/elimination of symptoms). 1
Intolerance of Adderall adverse events (e.g., insomnia, appetite suppression, anxiety, cardiovascular effects). 4, 1
Comorbid conditions such as tics, anxiety, or depression, where atomoxetine may offer additional benefits. 4, 2
Substance abuse risk or diversion concerns, as atomoxetine is not a controlled substance and has negligible abuse potential. 6, 2
Need for 24-hour symptom coverage, as atomoxetine's therapeutic effects extend through the waking hours into late evening and, in some patients, through to early the next morning. 4

Common Pitfalls to Avoid

Do not stop Adderall abruptly without starting atomoxetine first—this leaves the patient without ADHD coverage for 3–8 weeks. 2, 3
Do not assume atomoxetine will work as quickly as Adderall—set realistic expectations that full response may take 6–12 weeks. 2, 3
Do not underdose atomoxetine—the target dose is 60–100 mg daily for adults, and doses below 40 mg are often subtherapeutic. 5, 6, 2
Do not discontinue atomoxetine prematurely—a trial of at least 6–8 weeks is necessary to assess efficacy. 4, 3
Do not forget cardiovascular monitoring—both Adderall and atomoxetine affect blood pressure and heart rate, and the combination may produce additive effects. 4, 1, 2

Expected Outcomes

Mean ADHD symptom scores improve significantly from baseline to endpoint (e.g., ADHD-RS-IV total scores improved from 32.1 to 22.6 in one study, p < 0.001). 1
Approximately 65% of patients report a preference for atomoxetine over their previous stimulant after completing the transition. 1
Atomoxetine is effective in relapse prevention and may have positive effects on global functioning, health-related quality of life, self-esteem, and social/family functioning. 4, 2

If Atomoxetine Fails After 6–8 Weeks

Consider switching back to a stimulant (either Adderall or an alternative like methylphenidate), as approximately 50% of stimulant non-responders will respond to atomoxetine, meaning 50% will not. 4
Consider alternative non-stimulants such as extended-release guanfacine (effect size ~0.7) or extended-release clonidine, particularly if comorbid anxiety, tics, or sleep disturbances are present. 7, 8
Ensure the atomoxetine dose was adequate (60–100 mg daily) and the trial duration was sufficient (at least 6–8 weeks). 4, 3

What is the safest way to transition a patient with ADHD from Adderall (mixed amphetamine salts) to atomoxetine (Strattera), including taper schedule, overlap dosing, and monitoring?

Help us tailor your experience